June 12, 2019 As reported by The Rheumatologist, Dr. Richard Furie provided his perspective on clinical trials in lupus in a talk for the American College of Rheumatology meeting. “Lupus is being attacked in a very eclectic manner. It’s just fascinating to me how many different approaches are being taken to attack this condition,” he …
Tag: BIIB059
Positive Early Results for BIIB059 as New Treatment Strategy
March 1, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of lupus. For this reason, type I interferons are a very attractive target for lupus drug development. In 2015, excitement surrounded the release of positive phase II data with anifrolumab, a therapeutic antibody that blocks type …